Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Veloxis Pharmaceuticals A/S    VELO   DK0060048148

VELOXIS PHARMACEUTICALS A/S (VELO)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
09/12/2018 09/13/2018 09/14/2018 09/17/2018 09/18/2018 Date
1.052(c) 1.042(c) 1.048(c) 1.02(c) 1.02(c) Last
135 544 578 334 312 529 607 046 511 426 Volume
+0.19% -0.95% +0.58% -2.67% 0.00% Change
More quotes
Financials (DKK)
Sales 2018 269 M
EBIT 2018 -26,3 M
Net income 2018 -59,1 M
Debt 2018 204 M
Yield 2018 -
Sales 2019 388 M
EBIT 2019 52,6 M
Net income 2019 13,1 M
Debt 2019 230 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 7,21x
EV / Sales2019 5,08x
Capitalization 1 738 M
More Financials
Company
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients.The company is focused on the direct commercialization of Envarsus XR in the US,... 
More about the company
Latest news on VELOXIS PHARMACEUTICALS A/
08/24VELOXIS PHARMACEUTICALS A/S : Increases Share Capital in Connection with Exercis..
AQ
08/23VELOXIS PHARMACEUTICALS A/S : Increases Share Capital in Connection with Exercis..
AQ
08/16VELOXIS PHARMACEUTICALS A/S : Researchers Submit Patent Application, "Solid Disp..
AQ
08/13VELOXIS PHARMACEUTICALS A/S : Announces Financial Results for the First Six Mont..
AQ
08/08VELOXIS PHARMACEUTICALS A/S : half-yearly earnings release
07/13VELOXIS PHARMACEUTICALS A/S : Grants Warrants Under Existing Warrant Program
AQ
06/04VELOXIS PHARMACEUTICALS A/S : Partners with the American Society of Transplant S..
AQ
05/18VELOXIS PHARMACEUTICALS A/S : Announces Financial Results for the First Three Mo..
AQ
05/16CORRECTION : Veloxis Pharmaceuticals Announces Financial Results for the First T..
PU
05/14VELOXIS PHARMACEUTICALS A/S : Announces Financial Results for the First Three Mo..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans -- U..
DJ
09/13Roche steps up efficiency drive to take sting out of biosimilars
RE
09/12EUROPE : European stocks shrug off trade worries as oil stocks rally
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
08/14Veloxis Pharmaceuticals Announces Financial Results for the First Six Months .. 
08/13Veloxis Pharmaceuticals $VELO Announces Financial Results for the First Six M.. 
08/13RT TFTCS "New post: "Veloxis Pharmaceuticals Announces Financial Results for .. 
08/13Veloxis Pharmaceuticals reports 1H results  
05/17/C O R R E C T I O N -- Veloxis Pharmaceuticals/  
More tweets
Qtime:5
News from SeekingAlpha
08/13Veloxis Pharmaceuticals reports 1H results 
05/15Veloxis Pharmaceuticals  reports Q1 results 
2016Veloxis Pharmaceuticals reports 1H16 results 
2015Veloxis Pharma's once-daily Envarsus an Orphan Drug for prevention of organ r.. 
2015PREMARKET BIOTECH DIGEST : Pfizer In China, Anavex Alzheimer's Focus 
Chart VELOXIS PHARMACEUTICALS A/S
Duration : Period :
Veloxis Pharmaceuticals A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VELOXIS PHARMACEUTICALS A/
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 1,33  DKK
Spread / Average Target 30%
EPS Revisions
Managers
NameTitle
Craig A. Collard President & Chief Executive Officer
Michael Thomas Heffernan Chairman
Stacy Wheeler Vice President-Operations
Morten Marott Chief Financial Officer
Ulf Meier-Kriesche Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
VELOXIS PHARMACEUTICALS A/S18.60%272
CELLTRION, INC.--.--%33 722
IQVIA HOLDINGS INC27.75%25 338
LONZA GROUP20.13%24 487
INCYTE CORPORATION-28.11%14 247
SEATTLE GENETICS, INC.46.09%12 094